DEFA14A: Hologic Acquired by Blackstone, TPG for Long-Term Growth

Hologic, Inc. announces its agreement to be acquired by private equity firms Blackstone and TPG, shifting from public to private ownership with a focus on long-term strategic growth.

Summary

• Hologic, Inc. has entered into an agreement to be acquired by private equity firms Blackstone and TPG.
• The acquisition will transition Hologic from being owned by numerous public investors to a select group of private investors, led by Blackstone and TPG.
• The new ownership structure is expected to shift the company's focus from short-term quarterly results to long-term performance over several years.
• Strategies for accelerating growth under private ownership are anticipated to include increased investments in R&D, commercial operations, global markets, and potential acquisitions of other companies.
• Blackstone and TPG are acquiring Hologic due to their admiration for its 40-year history in improving women's health and their intent to build upon this legacy.
• The vast majority of employees are not expected to experience significant changes in their day-to-day jobs following the acquisition.
• The transaction is projected to close in the first half of calendar year 2026.
• Employees are encouraged to maintain focus on current plans, commitments, and execution during the transition period.

Sentiment

Score: 8

Explanation: The tone is highly positive and optimistic, emphasizing long-term growth, strategic investments, and minimal disruption for employees under new private ownership. Management expresses confidence in the future partnership and the strategic benefits of the acquisition.

Positives

• Transition to private ownership by Blackstone and TPG enables a longer-term strategic focus, moving away from the pressures of short-term quarterly results.
• Potential for accelerated growth through increased investments in R&D, commercial expansion, global market penetration, and strategic acquisitions.
• Acquirers value Hologic's mission in women's health and intend to build on its established legacy.
• Minimal day-to-day job changes are expected for the majority of employees, promoting stability.
• The partnership with Blackstone and TPG is anticipated to lead to an 'even brighter future' for the company.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay or prevent the consummation of the proposed transaction.
• The occurrence of any event, change, or other circumstances could give rise to the termination of the merger agreement.
• Hologic stockholders may not approve the proposed transaction.
• The parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• The proposed transaction could disrupt management time from ongoing business operations.
• Announcements related to the proposed transaction could adversely affect the market price of Hologic's common stock.
• There is a risk of unexpected costs or expenses resulting from the proposed transaction.
• The proposed transaction carries a risk of litigation.
• The proposed transaction and its announcement could adversely affect Hologic's ability to retain and hire key personnel and maintain relationships with customers, vendors, partners, employees, stockholders, and other business relationships, impacting operating results and business generally.
• Holders of Contingent Value Rights (CVRs) may receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction.

Future Outlook

The company anticipates an 'even brighter future' under the new private ownership, with a focus on accelerating long-term growth through increased investments in R&D, commercial activities, global expansion, and potential acquisitions. The shift to private ownership is expected to free the company from the short-term pressures of public markets, allowing for a more sustained strategic approach.

Management Comments

• "One way to understand this transaction, at the highest level, is that we're getting a new set of shareholders."
• "Blackstone and TPG are focused on our performance over the next several years, so we can escape the quarterly grind."
• "For our new shareholders, the most important thing is accelerating growth over the long term."
• "The strategies probably include making more investments — investments in R&D, in commercial, in global markets, and in buying other companies."
• "Blackstone and TPG are buying us because they admire what we've accomplished over the last 40 years to improve women's health, and they want to build on it."
• "The vast majority of employees won't see much change in their day-to-day jobs after the acquisition."
• "Nothing is changing right now. The transaction is expected to close in the first half of calendar 2026."
• "Our customers are counting on us, our patients are counting on us, and our future owners are counting on us."

Industry Context

The acquisition of Hologic by private equity firms Blackstone and TPG reflects a broader trend of private capital seeking opportunities in the healthcare and medical technology sectors. This strategy often targets established companies with strong market positions and potential for long-term growth, allowing for strategic investments and restructuring away from the immediate pressures of public market quarterly reporting. Such moves can enable companies to pursue more ambitious, longer-term initiatives without constant public scrutiny.

Corporate Governance

Legal Proceedings

• There is a risk of litigation relating to the proposed transaction.

Stakeholder Impact

• Shareholders: Will receive consideration for their shares as part of the acquisition, transitioning from public to private ownership.
• Employees: The vast majority are not expected to see significant day-to-day job changes, with management emphasizing continued focus and dedication.
• Customers & Patients: Expected to benefit from a stronger company due to increased investments in R&D and global markets, potentially leading to improved products and services.
• Vendors & Partners: Maintaining relationships with these parties is identified as a risk factor, implying efforts to ensure continuity.

Next Steps

• Hologic will file a Proxy Statement with the SEC in connection with the proposed acquisition.
• Hologic plans to mail a definitive Proxy Statement to its stockholders.
• Stockholders are urged to read the Proxy Statement and other relevant documents filed or to be filed with the SEC.
• The parties must obtain all required governmental and regulatory approvals for the transaction.
• Hologic stockholders must approve the proposed transaction.
• The parties to the merger agreement must satisfy all conditions to the proposed transaction.
• The transaction is expected to close in the first half of calendar 2026.

Key Dates

Recommendation

The company is subject to an agreed acquisition by Blackstone and TPG, with the transaction expected to close in the first half of 2026. For existing shareholders, the decision to sell or hold depends on the offer price relative to the current market price and any potential Contingent Value Rights (CVRs). For new investors, the stock price will likely trade close to the acquisition price, limiting significant upside or downside until closing. Therefore, a 'hold' position is appropriate while awaiting transaction completion, as the primary value driver is the closing of the acquisition.

Keywords

Hologic, Blackstone, TPG, acquisition, private equity, women's health, medical technology, merger, corporate governance, R&D investment, global markets